IP Library › Granted Patent US 9,617,218
Granted Patent B2
US 9,617,218 · App. 14/805,345 · Granted Apr 11, 2017

Crystalline forms of a prolyl hydroxylase inhibitor

Inventors: Claudia Witschi (San Francisco, CA); Jung Min Park (San Francisco, CA); Michael D. Thompson (Redwood City, CA); Michael John Martinelli (San Francisco, CA); David A. Yeowell (Chapel Hill, NC); Michael P. Arend (Foster City, CA)
Assignee: FibroGen, Inc.
C07D217/26A61K31/47
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,617,218
App. No.
14/805,345
Granted
Apr 11, 2017
Kind
B2
Abstract

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.

Claims (6)

1. A composition comprising crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound A Form A), wherein at least about 85% of Compound A is in Form A.

2. The composition of claim 1 , wherein the Compound A Form A is characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 223° C.

3. The composition of claim 2 , wherein the DSC curve is substantially as shown in FIG. 2 .

4. The composition of claim 1 , wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising a peak at 8.5 °2θ±0.2°2θ.

5. The composition of claim 1 , wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising a peak at 16.2 °2θ±0.2°2θ.

6. The composition of claim 1 , wherein the Compound A Form A is characterized by an X-ray powder diffractogram comprising a peak at 27.4 °2θ±0.2°2θ.

Assignments (4)
CHANGE OF NAME Recorded Feb 18, 2026
From: FIBROGEN, INC.
To: KYNTRA BIO, INC.
Reel/Frame 074923/0352 →
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2015
From: WITSCHI, CLAUDIA; PARK, JUNG MIN; THOMPSON, MICHAEL D.; MARTINELLI, MICHAEL JOHN; YEOWELL, DAVID A.; AREND, MICHAEL P.
To: FIBROGEN, INC.
Reel/Frame 036752/0804 →
Continuity (5)
Continuation 13942443 · Jul 15, 2013
Provisional Application 61768297 · Feb 22, 2013
Provisional Application 61672191 · Jul 16, 2012
Provisional Application 61832566 · Jun 7, 2013
Related Publication 20150322015A1 · Nov 12, 2015